RxDoctor Payments DataLook up a doctor →

Sunil Kalla, MD

Cardiovascular Disease · Henderson, NVNPI 1699726240

Payments from drug & device makers

$15,794in general payments, 2019–2025

Across 515 payments — averaging $30.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Asahi Intecc USA, Inc.$1K
  • Amgen$1K
  • Boston Scientific$985
  • Novartis$941
  • Penumbra, Inc.$771
  • plus $9K from 40 others

What the payments were for

  • Travel & lodging$6894%
  • Food & beverage$15,02795%
  • Education$780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,794 in reported general payments places this provider in the 75th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$788,296
Medicare patients
1,509
Services billed
6,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$217,346
XareltoRivaroxaban117$154,063
Repatha SureclickEvolocumab88$104,499
EntrestoSacubitril/Valsartan61$93,165
JardianceEmpagliflozin43$50,089
MultaqDronedarone Hcl18$26,196
FarxigaDapagliflozin Propanediol36$25,012
VerquvoVericiguat25$21,441
BrilintaTicagrelor19$21,354
Ranolazine ErRanolazine53$4,605
Atorvastatin Calcium368$3,848
EdarbyclorAzilsartan Med/Chlorthalidone13$3,677
Metoprolol Succinate217$3,303
Carvedilol258$2,118
Nebivolol Hcl47$1,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$217,346186 claims
Johnson & JohnsonXarelto$290$154,063117 claims
NovartisEntresto$941$93,16561 claims
Boehringer IngelheimJardiance$197$50,08943 claims
AstraZenecaFarxiga, Brilinta$302$46,36655 claims
Sanofi-aventis U.S. LLCMultaq$489$26,19618 claims
MerckVerquvo$682$21,44125 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$12$3,67713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →